scholarly journals A retrospective analysis of safety and efficacy of weekly nab-paclitaxel as second-line chemotherapy in elderly patients with advanced squamous non-small-cell lung carcinoma

2016 ◽  
pp. 167 ◽  
Author(s):  
Jinming Yu ◽  
Feng Jin ◽  
Hui Zhu ◽  
Fang Shi ◽  
Li Kong
Keyword(s):  
Elderly Patients ◽  
Retrospective Analysis ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Second Line ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Safety And Efficacy ◽  
Line Chemotherapy

Clinical Features And Outcomes Of Patients With Small Cell Lung Carcinoma; Retrospective Analysis

2015 ◽  
Vol 3 (2) ◽  
pp. 47 ◽  
Author(s):  
Duygu Unalmış ◽  
Zehra Yasar ◽  
Melih Buyuksirin ◽  
Gulru Polat ◽  
Fatma Demirci Ucsular ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Clinical Features ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma

scholarly journals A comparative study of immunotherapy as second-line treatment and beyond in patients with advanced non-small-cell lung carcinoma

2021 ◽  
pp. LMT47
Author(s):  
Jerónimo Rafael Rodríguez-Cid ◽  
Sonia Carrasco-Cara Chards ◽  
Iván Romarico González-Espinoza ◽  
Vanessa García-Montes ◽  
Julio César Garibay-Díaz ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Objective Response ◽  
Small Cell ◽  
Immune Checkpoints ◽  
Line Treatment ◽  
Second Line ◽  
Small Cell Lung ◽  
Total Study Population ◽  
Cell Lung Carcinoma

Background: Immunotherapy has demonstrated an improved overall survival (OS) and progression-free survival (PFS) as second-line treatment and subsequent lines compared with chemotherapy.  Materials and methods: This was a retrospective review among eight medical centers comprising 100 patients with a confirmed diagnosis of non-small-cell lung carcinoma, in their second-line treatment or beyond with immune checkpoints inhibitors treatment. The current study aimed to analyze effectiveness of immunotherapy in second-line treatment or further in the Mexican population, using PFS rate, OS rate and the best objective response to treatment by RECIST 1.1 as a surrogate of effectiveness. Results: In total, 100 patients met the criteria for enrollment in the current study. From the total study population, 49 patients (49.0%) were male and 51 (51.0%) were female, with an average age of 60 years and stage IV as the most prevalent clinical stage at the beginning of the study. A total of 61 patients (61.0%) had partial response; 11 (11.0%) stable disease; 2 (2.0%), complete response, 4 (4.0%), progression; and 22 (22.0%) were nonevaluable. We found a median PFS of 4 months (95% CI: 3.2–4.7 months) and an OS of 9 months (95% CI: 7.2–10.7 months). Conclusion: The response to immunotherapy is similar, with an improvement in OS and PFS, independent of which drug is used. Patients using nivolumab had a better survival, although that was not statistically significant.

Ifosfamide and Vinorelbine as First-Line Chemotherapy for Advanced Non-Small Cell Lung Carcinoma

1996 ◽  
Vol 19 (6) ◽  
pp. 584-588 ◽  
Author(s):  
C. Vallejo ◽  
A. Romero ◽  
J. Perez ◽  
M. Cuevas ◽  
J. Lacava ◽  
...  
Keyword(s):  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Small Cell Lung ◽  
First Line ◽  
Cell Lung Carcinoma ◽  
Line Chemotherapy

scholarly journals Trimodal therapy for stage III-N2 non-small-cell lung carcinoma: a single center retrospective analysis

BMC Cancer ◽  
2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Vasileios Askoxylakis ◽  
Judith Tanner ◽  
Jutta Kappes ◽  
Hans Hoffmann ◽  
Nils H Nicolay ◽  
...  
Keyword(s):  
Retrospective Analysis ◽  
Lung Carcinoma ◽  
Small Cell Lung Carcinoma ◽  
Small Cell ◽  
Stage Iii ◽  
Single Center ◽  
Small Cell Lung ◽  
Cell Lung Carcinoma ◽  
Trimodal Therapy
Sign in / Sign up

Export Citation Format

Share Document